NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free OCUL Stock Alerts $4.20 -0.44 (-9.48%) (As of 04:33 PM ET) Add Compare Share Share Today's Range$4.16▼$4.5150-Day Range$4.65▼$10.9352-Week Range$2.00▼$11.31Volume4.68 million shsAverage Volume2.19 million shsMarket Capitalization$649.74 millionP/E RatioN/ADividend YieldN/APrice Target$17.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ocular Therapeutix alerts: Email Address Ocular Therapeutix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside317.1% Upside$17.60 Price TargetShort InterestBearish9.47% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews Sentiment0.42Based on 13 Articles This WeekInsider TradingAcquiring Shares$7 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.53 out of 5 starsMedical Sector274th out of 907 stocksPharmaceutical Preparations Industry115th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.47% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Ocular Therapeutix has recently increased by 24.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 1.9 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Ocular Therapeutix this week, compared to 3 articles on an average week.Search InterestOnly 18 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have bought 3,492.29% more of their company's stock than they have sold. Specifically, they have bought $7,000,000.00 in company stock and sold $194,862.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to remain at ($0.68) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Ocular Therapeutix Stock (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUL Stock News HeadlinesApril 24, 2024 | fool.com2 Small-Cap Growth Stocks With Room To RunApril 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD PotentialApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 21, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Ocular Therapeutix (NASDAQ:OCUL)April 21, 2024 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Sees Large Volume IncreaseApril 20, 2024 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 9.2% April 19, 2024 | msn.comBaird sees weakness in Ocular shares as "overdone"April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 18, 2024 | marketwatch.comOcular Therapeutix Shares Dive on Axpaxli Trial ResultsApril 18, 2024 | markets.businessinsider.comOcular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDRApril 18, 2024 | seekingalpha.comOcular marks early-stage trial win for diabetic retinopathy candidateApril 18, 2024 | globenewswire.comOcular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic RetinopathyApril 17, 2024 | theglobeandmail.comAge-related Vision Dysfunction Market Size in the 7MM is anticipated to increase by 2032, estimates DelveInsightApril 17, 2024 | uk.investing.comOcular Therapeutix appoints new CEO amid leadership shiftApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)April 17, 2024 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Given Market Outperform Rating at JMP SecuritiesApril 16, 2024 | markets.businessinsider.comThe Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 ExpertsApril 16, 2024 | stockhouse.comOcular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal LeadersApril 16, 2024 | finance.yahoo.comOcular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal LeadersApril 16, 2024 | americanbankingnews.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Buy" from AnalystsApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | marketwatch.comOcular Therapeutix CEO Mattessich Steps Down, Executive Chairman Fills RoleApril 15, 2024 | markets.businessinsider.comOcular Therapeutix CEO Mattessich To Step Down, Dugel To SucceedApril 15, 2024 | globenewswire.comOcular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEOApril 13, 2024 | msn.comRemedies Recommended For Ocular RosaceaApril 9, 2024 | globenewswire.comOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of BiometricsSee More Headlines Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees267Year FoundedN/APrice Target and Rating Average Stock Price Target$17.60 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside+319.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,740,000.00 Net Margins-138.15% Pretax Margin-138.15% Return on Equity-321.12% Return on Assets-53.93% Debt Debt-to-Equity Ratio0.82 Current Ratio6.66 Quick Ratio6.59 Sales & Book Value Annual Sales$58.44 million Price / Sales11.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book5.32Miscellaneous Outstanding Shares154,700,000Free Float146,195,000Market Cap$649.74 million OptionableOptionable Beta1.30 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Antony Mattessich (Age 56)President, CEO & Director Comp: $1.05MMr. Donald Notman Jr.Chief Financial OfficerDr. Jeffrey S. Heier M.D. (Age 63)Chief Scientific Officer Comp: $84.88kDr. Rabia Gurses Ozden M.D. (Age 55)Chief Medical Officer Comp: $621.39kDr. Pravin U. Dugel M.D. (Age 60)Executive Chairman Dr. Karen-Leigh Edwards M.B.A.Ph.D., Chief Operations OfficerDr. Peter K. Jarrett Ph.D. (Age 67)Chief Technology Officer Mr. Philip C. Strassburger Esq. (Age 64)General Counsel Comp: $282.61kMr. William H. Ransone IIVice President of Global Sales & MarketingMs. Tracy SmithVice President of Human ResourcesMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHArcturus TherapeuticsNASDAQ:ARCTPliant TherapeuticsNASDAQ:PLRXLongboard PharmaceuticalsNASDAQ:LBPHALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsSimplicity Wealth LLCBought 28,987 shares on 4/24/2024Ownership: 0.019%Deltec Asset Management LLCSold 79,523 shares on 4/17/2024Ownership: 1.591%Trust Co. of VermontBought 1,000 shares on 3/8/2024Ownership: 0.008%Summer Road LlcBought 930,851 shares on 2/26/2024Total: $7.00 M ($7.52/share)Virtu Financial LLCBought 62,066 shares on 2/26/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions OCUL Stock Analysis - Frequently Asked Questions Should I buy or sell Ocular Therapeutix stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares. View OCUL analyst ratings or view top-rated stocks. What is Ocular Therapeutix's stock price target for 2024? 5 brokers have issued 1-year price objectives for Ocular Therapeutix's shares. Their OCUL share price targets range from $15.00 to $24.00. On average, they expect the company's share price to reach $17.60 in the next twelve months. This suggests a possible upside of 317.1% from the stock's current price. View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts. How have OCUL shares performed in 2024? Ocular Therapeutix's stock was trading at $4.46 at the beginning of the year. Since then, OCUL shares have decreased by 5.4% and is now trading at $4.22. View the best growth stocks for 2024 here. Are investors shorting Ocular Therapeutix? Ocular Therapeutix saw a increase in short interest in April. As of April 15th, there was short interest totaling 14,650,000 shares, an increase of 24.0% from the March 31st total of 11,810,000 shares. Based on an average daily volume of 2,330,000 shares, the short-interest ratio is presently 6.3 days. View Ocular Therapeutix's Short Interest. When is Ocular Therapeutix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our OCUL earnings forecast. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings results on Monday, March, 11th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28). The biopharmaceutical company had revenue of $14.80 million for the quarter, compared to analyst estimates of $15.31 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 321.12% and a negative net margin of 138.15%. What ETFs hold Ocular Therapeutix's stock? ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL). What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.59%) and Simplicity Wealth LLC (0.02%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCUL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
